NASDAQ · ANIP
ANI Pharmaceuticals, Inc.
$77.65 -$0.88 (-1.12%) 1D After hours
Session Pulse
After hours
1
mentions on Fri
· 1 bullish
/ 0 bearish tags
No new SEC filings since Mon close
its sector ranked
6/11
this week
Full pulse →
Key Metrics
$1.79B
Market cap
19.37×
P/E · TTM
$923.71M
Revenue · TTM
$92.15M
Net income
EPS · TTM
$4.60
Dividend yield
0.0%
Free cash flow
$191.17M
Beta · 1Y
0.45
EBITDA · TTM
—
Gross margin
—
Snapshot
Market cap$1.79B
Enterprise value$1.78B
Shares outstanding22.7M
52-wk range$62.61 – $99.50
Avg volume · 20D202.7K
Net cash
$5.88M
Book value / share$28.05
IndustryPharmaceutical Preparations
ExchangeNASDAQ
About ANI Pharmaceuticals, Inc.
IPO dateSep 13, 1999
Employees970
ANI Pharmaceuticals Inc is a diversified biopharmaceutical company.
Wolf Grade COMING SOON
—
The wolf is in training. Composite grades vs sector — profitability, health, value, momentum — arrive with the percentile engine. Methodology will be public.
Valuation
P/E19.37
P/S1.93
P/FCF9.34
EV/EBITDA—
EV/Sales1.93
Graham №$53.86
Profitability
Gross
—
Operating
12.6%
Net
10.0%
FCF
20.7%
ROE / ROIC
19.1% · 16.6%
Financial Health
Current ratio3.12
Quick ratio2.52
Debt / equity0.54
Debt / EBITDA
—
Net cash
$5.88M
Working capital$507.57M
Cash Flow · TTM
Operating CF
$208.61M
Capex
−$17.44M
Free cash flow
$191.17M
Buybacks
$21.96M
Dividends paid
$751.00K
Shareholder yield
1.3%
Piotroski F-Score
6 / 9
Middling fundamentals · 6 of 9 signals passing
Altman Z-Score
2.6
Grey zone (1.81–2.99) · monitor
Graham Number vs Price
$53.86 vs $77.65
Trades 1.4× above classic defensive value — priced for growth
Fundamentals through 2026-03-31 · computed by TickerWolf from SEC filings